Imagine a swarm of tiny, wireless robots that can be placed in the brain to act like a smart thermostat for neural activity. Instead of just using electricity, they can use heat, light, or movement to calm down a brain storm like an epileptic seizure. These bots talk to each other and a wearable device to adjust treatment in real-time based on what the brain is doing.
Current brain stimulation tools are often too invasive or lack the precision to treat complex neurological disorders like epilepsy without causing significant tissue scarring or side effects.
A system of wireless µBots and a neuromorphic controller chip capable of sensing and stimulating brain tissue using electrical, thermal, and mechanical means.
If you are a neurotechnology manufacturer dealing with the limitations of bulky, invasive brain implants — this project developed µBots that provide multi-modal stimulation (electrical, mechanical, optical, thermal) to treat epilepsy and Parkinson's with higher precision.
If you are a biotech company dealing with the difficulty of delivering genetic material to specific brain circuits — this project developed endovascularly implanted bots that deliver genetic material upon command.
If you are a chip designer dealing with high power consumption in implantable AI — this project developed a modular neuromorphic controller with ultra-low-power memristive synapses for real-time brain signal decoding.
Based on available project data, there is no information regarding the unit cost or commercial pricing of the devices.
The project has reached a functional prototype stage in vitro; however, data on industrial scaling processes is not provided.
Based on available project data, specific patent filings or licensing terms are not listed, though a modular controller chip has been fabricated.
The project includes social sciences and ethics to assess regulatory acceptability and has tested biocompatibility in neuronal cultures and organotypic brain slices.
The project period runs until 2026-10-31, with current evidence showing testing in neuronal cultures and animal models of Parkinson's and Epilepsy.
The consortium is heavily research-oriented, consisting of 5 universities and 5 research institutions, with only 1 industry partner (SME). This 9% industry ratio suggests the project is currently focused on high-risk technical validation and fundamental breakthroughs rather than immediate commercialization.
Contact Università degli Studi di Roma Tor Vergata
Contact us to explore licensing opportunities for the neuromorphic controller chip.
